)
)
)
AltRegen
AltRegen is a clinical stage biotechnology company developing ATR211, the first oral therapy for age-related macular degeneration (AMD). By restoring Bruch’s membrane function, ATR211 offers a disease modifying approach that addresses the root cause of vision decline in people over 50. ATR211 is now in a Phase 2b clinical trial in the UK in collaboration with leading academic centers. Founded in 2016, AltRegen has built strong expertise in macular degeneration, retinal biology, and translational ophthalmology. We are actively seeking global out-licensing, co-development partnerships, strategic collaborations, and M&A opportunities with pharmaceutical companies, biotech investors, and venture groups.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)